Christopher J. Kirk - 20 Jul 2023 Form 4 Insider Report for Kezar Life Sciences, Inc. (KZR)

Role
Director
Signature
/s/ Marc Belsky, Attorney-in-fact
Issuer symbol
KZR
Transactions as of
20 Jul 2023
Net transactions value
+$44,055
Form type
4
Filing time
24 Jul 2023, 16:20:53 UTC
Previous filing
10 Jan 2023
Next filing
26 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KZR Common Stock Options Exercise $44,055 +48,950 +13% $0.9000 431,348 20 Jul 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KZR Employee Stock Option (right to buy) Options Exercise $0 -48,950 -40% $0.000000 74,411 20 Jul 2023 Common Stock 48,950 $0.9000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Total reflects 914 shares of common stock acquired on November 15, 2022 through the Company's 2018 Employee Stock Purchase Plan.
F2 Fully vested and exercisable.